169 related articles for article (PubMed ID: 10850352)
1. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
3. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
4. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
Dillman R; Selvan S; Schiltz P; Peterson C; Allen K; Depriest C; McClay E; Barth N; Sheehy P; de Leon C; Beutel L
Cancer Biother Radiopharm; 2004 Oct; 19(5):658-65. PubMed ID: 15650459
[TBL] [Abstract][Full Text] [Related]
6. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
Dillman RO; DePriest C; DeLeon C; Barth NM; Schwartzberg LS; Beutel LD; Schiltz PM; Nayak SK
Cancer Biother Radiopharm; 2007 Jun; 22(3):309-21. PubMed ID: 17651037
[TBL] [Abstract][Full Text] [Related]
7. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
Dillman RO; DeLeon C; Beutel LD; Barth NM; Schwartzberg LS; Spitler LE; Garfield DH; O'Connor AA; Nayak SK
Crit Rev Oncol Hematol; 2001; 39(1-2):115-23. PubMed ID: 11418308
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
Dillman R; Barth N; Selvan S; Beutel L; de Leon C; DePriest C; Peterson C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):581-8. PubMed ID: 15650450
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
10. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
13. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R
Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914
[TBL] [Abstract][Full Text] [Related]
14. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
Mahvi DM; Shi FS; Yang NS; Weber S; Hank J; Albertini M; Schiller J; Schalch H; Larson M; Pharo L; Gan J; Heisey D; Warner T; Sondel PM
Hum Gene Ther; 2002 Sep; 13(14):1711-21. PubMed ID: 12396624
[TBL] [Abstract][Full Text] [Related]
15. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
16. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Baars A; Claessen AM; van den Eertwegh AJ; Gall HE; Stam AG; Meijer S; Giaccone G; Meijer CJ; Scheper RJ; Wagstaff J; Vermorken JB; Pinedo HM
Ann Oncol; 2000 Aug; 11(8):965-70. PubMed ID: 11038032
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma.
Leong SP; Enders-Zohr P; Zhou YM; Stuntebeck S; Habib FA; Allen RE; Sagebiel RW; Glassberg AB; Lowenberg DW; Hayes FA
J Immunother; 1999 Mar; 22(2):166-74. PubMed ID: 10093041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
